Immunic, Inc.
IMUX
$16.06
-$0.52-3.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 78.70% | -28.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.47% | -10.26% | |||
| Operating Income | -42.47% | 10.26% | |||
| Income Before Tax | -68.85% | 24.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -68.85% | 24.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -68.85% | 24.55% | |||
| EBIT | -42.47% | 10.26% | |||
| EBITDA | -42.59% | 10.28% | |||
| EPS Basic | -8.88% | 24.71% | |||
| Normalized Basic EPS | -19.38% | 31.34% | |||
| EPS Diluted | -8.88% | 24.71% | |||
| Normalized Diluted EPS | -19.38% | 31.34% | |||
| Average Basic Shares Outstanding | 55.09% | 0.22% | |||
| Average Diluted Shares Outstanding | 55.09% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||